In Vivo Compound Profiling
In evaluating the clinical development profile of your drug candidate, have you ever needed strong in vivo efficacy data, suspected any off-target effects, determined involvement of multiple protein targets, and/or identified adverse safety effects that you wished you would have seen at the pre-clinical stage? Add in vivo Compound Profiling to your armamentarium of pre-clinical drug evaluation strategies.Screening compounds for their effect(s) on intracellular processes is a crucial piece of the drug discovery and development process. Thoughtfully designed preclinical drug studies are essential to the support of any Investigational New Drug application. In recent years, this has been especially true for most pharmaceutical companies, since the consequences of product candidate failures can be devastating, both scientifically and financially. Accordingly, there is a need to decide, much earlier in the process, if and when a preclinical drug development candidate is ready to enter human clinical trials, and how to recognize the greatest value while minimizing the escalating development costs for such candidates.
Although the pharmaceutical industry has invested prodigious amounts in novel discovery technologies with hopes of improving R&D productivity, the output has not improved, due in part, to the gap in productivity. This productivity problem, coupled with worldwide pressure on drug pricing, diminishing patent exclusivity periods, mounting challenges from generics and ever-increasing regulatory hurdles, has forced drug development personnel to focus on identifying new uses for existing drugs. The process of finding new uses outside the scope of the approved medical indication for existing drugs is also known as drug repositioning or reprofiling.
CDAS has long recognized the value that data obtained from animal models can bring to preclinical research. As such, we are pleased to introduce our new comprehensive in vivo compound profiling program: a customized battery of pharmacological tests to (i) assess the therapeutic efficacy of (optimized) lead compounds and/or drug development candidates by analyzing their effects on key physiological functions in animals, and (ii) screen for potential side effects caused by the administration of such compounds, and/or (iii) discover novel disease indications for such compounds that were not previously known, thus expanding the market potential of those drug candidates. Moreover, we expect that this program's greatest impact will be to expand the market potential of certain drugs or drug candidates through the discovery of critically important secondary/additional indications for marketed as well as preclinical/clinical development drug candidates.Our proprietary program allows compounds to be evaluated for efficacy in either acute or chronic dosing paradigms. Furthermore, our customers are offered access to a customized set of bioassays, including challenge assays, presently drawn from a battery of more than 85 pharmacologically-validated assays, where up to 500 parameters/data points may be measured. These assays are designed to identify efficacious readouts in most therapeutic areas, and the resulting data defines the physiological and behavioral profile of the targets being modulated by specific compounds. Isn’t it time to add multi-parameter phenotypic assays and in vivo expertise to your compound profiling strategy?
Moreover, CDAS's in vivo compound profiling platform is customizable to the following therapeutic areas:
• Allergic diseases
• Arthritis
• Cancer and Oncology
• Cardiovascular diseases
• Diabetes
• Gastrointestinal disorders
• Immunology and inflammation
• Neurodegenerative disorders
• Obesity
• Osteoporosis
• Psychiatric Disorders
• Pain
• Sexual Health
• Tissue repair
• Urological disorders
For more information please review the related downloads, email us directly at compounds@caliperls.com or complete and submit the product inquiry form and a CDAS representative will contact you.
Back to CDAS - In Vivo (Overview) webpage